Abstract 622P
Background
CCL26 is widely found in various tissues of the human body and mainly acts on eosinophils. However, its role in tumors remains unclear. In this study, we aimed to investigate the role of CCL26 in pan-cancer.
Methods
Data were downloaded from University of California Santa Cruz (UCSC) Xena and The Cancer Genome Atlas (TCGA). The expression of CCL26 was investigated in TCGA_GTEx, TCGA and TCGA paired samples, respectively. Subsequently, Kaplan-Meier analyses were performed on 33 TCGA tumors, and clinical correlation and one-way Cox regression analyses were performed on tumors in which CCL26 affected prognosis. In addition, we selected more than 500 representative tumors of renal clear cell carcinoma (KIRC) to construct a nomogram model to confirm the prognostic value of CCL26 in the tumors. In addition, CCL26 there was an association with immune cell infiltration. Mechanistically, we performed functional enrichment analysis to explore potential signaling pathways in which CCL26 may be involved.
Results
Our study found that CCL26 expression was significantly up-regulated in 20 tumors and down-regulated in 6. High expression of CCL26 was associated with shorter overall survival (OS) in adrenocortical carcinoma (ACC), bladder uroepithelial carcinoma (BLCA), renal clear cell carcinoma (KIRC), papillary renal cell carcinoma (KIRP), and mesothelioma (MESO). CCL26 had high predictive accuracy (AUC > 0.9) for five cancers, including cholangiocarcinoma (CHOL; AUC = 0.952, CI: 0.890-0=1.000), renal smoky cell carcinoma (KICH; AUC = 0.928, CI: 0.875- 0.981), lung squamous cell carcinoma (LUSC; AUC = 0.928, CI: 0.905-0.951), skin melanoma (SKCM; AUC = 0.936, CI: NA-NA), thymoma (THYM; AUC = 0.933, CI: 0.829-1.000). -1.000).
Conclusions
CCL26 may serve as a potential prognostic biomarker and a promising target for cancer immunotherapy. It is also associated with clinical outcomes and immune microenvironment in a variety of tumors, and may influence tumor development by regulating signaling pathways of stem cell pluripotency and immune-related pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract